Ilyang Pharm (007570) — Capital Reinvestment Ratio
Ilyang Pharm (007570) has a Capital Reinvestment Ratio of 1.47x as of June 2025, meaning it reinvests 1% of its operating cash flow (₩2.26 Billion) in capital expenditures (₩3.32 Billion). Check 007570 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Ilyang Pharm Capital Reinvestment Ratio (2003–2024)
This chart tracks Ilyang Pharm's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see Ilyang Pharm (007570) cash conversion ratio.
Annual Capital Reinvestment Ratio for Ilyang Pharm (2003–2024)
Year-by-year Capital Reinvestment Ratio for Ilyang Pharm from 2003 to 2024. See Ilyang Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 7.23x | ₩5.61 Billion | ₩40.62 Billion | ▲ +1391.3% |
| 2023 | 0.49x | ₩13.34 Billion | ₩6.47 Billion | ▲ +255.8% |
| 2022 | 0.14x | ₩29.94 Billion | ₩4.08 Billion | ▼ -29.2% |
| 2021 | 0.19x | ₩67.02 Billion | ₩12.91 Billion | ▲ +8.8% |
| 2020 | 0.18x | ₩57.48 Billion | ₩10.17 Billion | ▲ +194.7% |
| 2019 | 0.06x | ₩36.19 Billion | ₩2.17 Billion | ▼ -14.1% |
| 2018 | 0.07x | ₩22.12 Billion | ₩1.55 Billion | ▼ -44.5% |
| 2017 | 0.13x | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.0% |
| 2016 | 0.38x | ₩26.98 Billion | ₩10.31 Billion | ▼ -4.3% |
| 2015 | 0.40x | ₩40.27 Billion | ₩16.07 Billion | ▼ -46.5% |
| 2014 | 0.75x | ₩18.63 Billion | ₩13.89 Billion | ▲ +1710.6% |
| 2003 | 0.04x | ₩10.08 Billion | ₩415.11 Million | — |